Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma; Neoadjuvant Therapies Interventions: Drug: Cardenilimab Combined With Chemotherapy Sponsors: Li Zhang Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma:A Prospective, Multicenter, Phase II Study
Conditions: Esophageal Squamous Cell Carcinoma; Neoadjuvant Therapies Interventions: Drug: Cardenilimab Combined With Chemotherapy Sponsors: Li Zhang Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
Effect of Cervical Paraesophageal Lymph Node Metastasis Versus Supraclavicular Lymph Node Metastasis on the Overall Survival of Patients With Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study
Conditions: Esophageal Cancer Sponsors: Sichuan Cancer Hospital and Research Institute Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Conditions: Head and Neck Squamous Cell Carcinoma Sponsors: Tempus Labs; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
Conditions: Melanoma Brain Metastases Interventions: Drug: Bevacizumab; Drug: Ipilimumab; Drug: Nivolumab; Radiation: Hypofractionated stereotactic radiotherapy Sponsors: Melanoma and Skin Cancer Trials Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors
Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 11, 2023 Category: Pharmaceuticals Source Type: clinical trials
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Conditions: Stage II Squamous Cell Carcinoma of the Head and Neck; Stage III Squamous Cell Carcinoma of the Head and Neck; Stage IV Squamous Cell Carcinoma of the Head and Neck Interventions: Drug: N-803; Drug: pembrolizumab; Biological: PD-L1 t-haNK cells Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection
Conditions: Esophageal Squamous Cell Carcinoma Thoracic Stage II; Esophageal Squamous Cell Carcinoma Thoracic Stage III; Esophageal Squamous Cell Carcinoma Thoracic Stage IV Interventions: Drug: sintilimab Sponsors: Fujian Medical University Union Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
Conditions: Small Cell Carcinoma of the Bladder; Small Cell Carcinoma of the Urinary Tract; Squamous Cell Carcinoma of the Bladder; Squamous Cell Carcinoma of the Urinary Tract; Primary Adenocarcinoma of the Bladder; Primary Adenocarcinoma of the Urinary Tract; Renal Medullary Carcinoma; Squamous Cell Carcinoma of the Penis Interventions: Drug: Sacituzumab govitecan; Drug: Atezolizumab Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A " Window of Opportunity " Pilot Study.
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Methylnaltrexone Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma
Conditions: Melanoma Interventions: Drug: Nivolumab +/- ipilimumab; Drug: Nivolumab Sponsors: Bristol-Myers Squibb Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)
Conditions: Facial Cutaneous Squamous Cell Carcinoma in Situ Interventions: Combination Product: Aminolevulinic Acid 20% Topical Solution with Blue Light Sponsors: The Center for Clinical and Cosmetic Research; Sun Pharmaceutical Industries Limited Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
CD40 Agonist and PD-1 Inhibitor in HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: PD-1inhibitor - LVGN 3616; Drug: CD 40 Agonist - LVGN 7409 Sponsors: University of Pennsylvania Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
A Single-arm, Prospective, Multi-center Phase II Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma
Conditions: Esophagus Cancer; Radiotherapy; Endoscopic Mucosal Resection Sponsors: Xiaomeng Zheng Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA Melanoma
Conditions: Clinical Stage IIA Cutaneous Melanoma AJCC v8 Interventions: Drug: Atorvastatin; Drug: Placebo Administration; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Other: Electronic Health Record Review Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University; Kuni Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2023 Category: Research Source Type: clinical trials
